BioCryst Pharmaceuticals Newswire

BioCryst Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for BioCryst Pharmaceuticals.

Results 1 - 20 of 272 in BioCryst Pharmaceuticals

  1. Analysts Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $5.89 MillionRead the original story w/Photo

    Friday Apr 21 | AmericanBankingNews.com

    Analysts predict that BioCryst Pharmaceuticals, Inc. will announce sales of $5.89 million for the current fiscal quarter, according to Zacks . Four analysts have provided estimates for BioCryst Pharmaceuticals' earnings.

    Comment?

  2. Somewhat Positive Press Coverage Very Likely to Affect BioCryst Pharmaceuticals (BCRX) Stock PriceRead the original story w/Photo

    Friday Apr 21 | Daily Political

    News articles about BioCryst Pharmaceuticals have trended somewhat positive this week, Alpha One Sentiment Analysis reports. Alpha One, a division of Accern, identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time.

    Comment?

  3. BioCryst Pharmaceuticals, Inc. (BCRX) CFO Thomas R. Staab II Sells 3,250 SharesRead the original story w/Photo

    Wednesday Apr 19 | The Breeze

    BioCryst Pharmaceuticals, Inc. CFO Thomas R. Staab II sold 3,250 shares of the firm's stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $9.20, for a total transaction of $29,900.00.

    Comment?

  4. BioCryst Pharmaceuticals, Inc. (BCRX) Expected to Announce Earnings of -$0.19 Per ShareRead the original story w/Photo

    Wednesday Apr 19 | IntersportsWire

    Wall Street brokerages expect BioCryst Pharmaceuticals, Inc. to report earnings per share for the current quarter, Zacks reports. Four analysts have made estimates for BioCryst Pharmaceuticals' earnings.

    Comment?

  5. BioCryst Pharmaceuticals, Inc. (BCRX) Upgraded to Buy by Zacks Investment ResearchRead the original story w/Photo

    Tuesday Apr 18 | AmericanBankingNews.com

    ... indicates a potential upside of 16.19% from the stock's current price. According to Zacks, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat ...

    Comment?

  6. BioCryst Pharmaceuticals (BCRX) Earns News Impact Score of 0.22Read the original story w/Photo

    Tuesday Apr 18 | Daily Political

    Media headlines about BioCryst Pharmaceuticals have been trending somewhat positive this week, AlphaOne Sentiment reports. AlphaOne, a unit of Accern, identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time.

    Comment?

  7. BioCryst Pharmaceuticals' (BCRX) Hold Rating Reiterated at Needham & Company LLCRead the original story w/Photo

    Tuesday Apr 18 | AmericanBankingNews.com

    BCRX has been the topic of a number of other research reports. JMP Securities raised BioCryst Pharmaceuticals from a market perform rating to an outperform rating and set a $10.00 price target on the stock in a research report on Friday, December 16th.

    Comment?

  8. BioCryst Pharmaceuticals, Inc. (BCRX) Short Interest UpdateRead the original story w/Photo

    Monday Apr 17 | IntersportsWire

    BioCryst Pharmaceuticals, Inc. was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 11,268,843 shares, a decline of 6.4% from the March 15th total of 12,040,792 shares.

    Comment?

  9. Research leads to new drug for hard-to-treat lymphomasRead the original story w/Photo

    Monday Apr 17 | PhysOrg Weblog

    ... at Victoria University of Wellington, New Zealand. Einstein licensed its PNP inhibitor portfolio to BioCryst Pharmaceuticals Inc. BioCryst subsequently entered into an exclusive sub-licensing agreement with Mundipharma to develop and commercialize ...

    Comment?

  10. Positive Press Coverage Extremely Likely to Impact BioCryst Pharmaceuticals (BCRX) Stock PriceRead the original story w/Photo

    Saturday Apr 15 | AmericanBankingNews.com

    Media stories about BioCryst Pharmaceuticals have been trending positive recently, according to Alpha One Sentiment. The research firm, a unit of Accern, ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time.

    Comment?

  11. BioCryst Pharmaceuticals, Inc. (BCRX) Stake Raised by Fmr LLCRead the original story w/Photo

    Friday Apr 14 | IntersportsWire

    Fmr LLC raised its position in BioCryst Pharmaceuticals, Inc. by 207.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission . The firm owned 737,723 shares of the biotechnology company's stock after buying an additional 498,161 shares during the period.

    Comment?

  12. BioCryst Pharmaceuticals, Inc. (BCRX) Stock Rating Reaffirmed by Needham & Company LLCRead the original story w/Photo

    Friday Apr 14 | IntersportsWire

    ... equities analysts have also commented on the stock. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating and set a $6.25 price objective for the company in a research note on Thursday, December ...

    Comment?

  13. State Street Corp Has $13.246 Million Position in BioCryst Pharmaceuticals, Inc.Read the original story w/Photo

    Thursday Apr 13 | IntersportsWire

    State Street Corp increased its stake in shares of BioCryst Pharmaceuticals, Inc. by 55.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,092,888 shares of the biotechnology company's stock after buying an additional 744,580 shares during the period.

    Comment?

  14. Federated Investors Inc. PA Has $531,000 Position in BioCryst Pharmaceuticals, Inc.Read the original story w/Photo

    Wednesday Apr 12 | The Breeze

    Federated Investors Inc. PA raised its stake in BioCryst Pharmaceuticals, Inc. by 3.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,835 shares of the biotechnology company's stock after buying an additional 2,983 shares during the period.

    Comment?

  15. Biocryst Expands Development Of BCX7353 To Explore Treatment Of Acute HAE AttacksRead the original story

    Tuesday Apr 11 | BioSpace

    BioCryst Pharmaceuticals, Inc. , a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, announced today plans to explore a new oral liquid formulation of BCX7353 for the treatment of acute attacks in patients with hereditary angioedema . The Company has received initial regulatory approvals in Europe to initiate the ZENITH-1 exploratory clinical trial this summer.

    Comment?

  16. BioCryst Pharmaceuticals, Inc. (BCRX) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    Wednesday Apr 12 | IntersportsWire

    According to Zacks, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza.

    Comment?

  17. BioCryst Pharmaceuticals (BCRX) Receiving Somewhat Positive Press Coverage, Report ShowsRead the original story w/Photo

    Friday Apr 7 | IntersportsWire

    News headlines about BioCryst Pharmaceuticals have been trending somewhat positive this week, Alpha One Sentiment reports. The research firm, a unit of Accern, identifies negative and positive press coverage by analyzing more than twenty million news and blog sources.

    Comment?

  18. Brokerages Set BioCryst Pharmaceuticals, Inc. (BCRX) Price Target at $9.00Read the original story w/Photo

    Thursday Apr 6 | IntersportsWire

    Shares of BioCryst Pharmaceuticals, Inc. have been assigned a consensus rating of "Buy" from the eight brokerages that are covering the company. Two investment analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company.

    Comment?

  19. BioCryst Pharmaceuticals, Inc. (BCRX) Given Consensus Recommendation of a oeBuya by BrokeragesRead the original story w/Photo

    Thursday Apr 6 | The Breeze

    Complete the form below to receive the latest headlines and analysts' recommendationsfor BioCryst Pharmaceuticals Inc. with our free daily email newsletter:

    Comment?

  20. Insider Selling: BioCryst Pharmaceuticals, Inc. (BCRX) Insider Sells 3,250 Shares of StockRead the original story w/Photo

    Thursday Apr 6 | IntersportsWire

    BioCryst Pharmaceuticals, Inc. insider Thomas R. Staab II sold 3,250 shares of the stock in a transaction dated Friday, March 10th. The stock was sold at an average price of $9.06, for a total transaction of $29,445.00.

    Comment?